迪瓦拉西布 (GDC-6036) 的发现和描述,它是KRAS G12C的强有力的共价抑制剂
Nicholas F Endres1, Steven Do1, Rana Mroue1
1Genentech, Inc., South San Francisco, California 94080, United States.
Journal of medicinal chemistry
|March 2, 2026
概括
迪瓦拉西布 (GDC-6036) 是一种强效的,选择性的KRAS G12C抑制剂,用于非小细胞肺癌. 它显示出强烈的抗瘤作用和快速的动力学,提供了一个有前途的新治疗方案.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- KRAS G12C突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 准KRAS G12C为NSCLC治疗提供了一个治疗策略.
研究的目的:
- 描述一种新型KRAS G12C抑制剂divarasib (GDC-6036) 的发现和优化.
- 为了评估divarasib的效力,选择性和抗瘤活性.
主要方法:
- 对divarasib的药物发现和优化过程.
- 在体外生化和细胞测试以评估抑制剂的功效和动力学.
- 在体内研究评估了KRAS G12C阳性模型中的瘤生长抑制.
主要成果:
- 迪瓦拉西布是一种口服可用的,强效和选择性的共价克拉斯G12C抑制剂.
- 迪瓦拉西布具有显著的非共价结合成分,有助于其强度和快速动力学.
- 实验室研究表明,divarasib比其他KRAS G12C抑制剂具有更大的效能和化动力学.
- 迪瓦拉西布在KRAS G12C阳性细胞系中表现出强大的瘤生长抑制.
结论:
- 迪瓦拉西布是KRAS G12C突变NSCLC的一种有前途的治疗候选药物.
- 迪瓦拉西布独特的结合特性有助于其增强的疗效.
- 对于NSCLC治疗,需要对divarasib进行进一步的临床研究.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.5K
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
3.2K
相关概念视频
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Small GTPases - Ras and Rho
5.6K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.6K
The Ras Gene
7.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.4K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
PI3K/mTOR/AKT Signaling Pathway
5.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.9K
